Dr. Yusuf Hamied, the Chairman of Cipla Ltd, was recently awarded the CNN – IBN Indian of the Year 2012 in the business category. Dr Hamid was awarded for his tireless and long standing contribution towards the Pharmaceutical Industry in India and for making essential medicines more affordable to the masses in developing countries.

Dr. Hamied has been actively involved with the pharmaceutical industry particularly, Cipla Ltd, the world’s largest manufacturer of generic antiretroviral drugs for over the past 50 years. He has played a significant role in ensuring that developing nations across the world become more self-sufficient and self-reliant in addressing their own health needs. Under Dr. Hamied’s stewardship Cipla has changed the landscape in the global pharmaceutical industry, building up an enviable reputation for Quality, Reliability and Sustainability of production. Cipla was established back in 1935 and during its 77 year legacy it has been able to set up 34 state-of-the-art manufacturing facilities approved by the major international regulatory agencies.

Cipla Ltd has a history of achievements and innovation and it is of no surprise that in Uganda they decided to set up a joint venture Quality Chemicals Limited (QCL) a company that shares a similar vision for making essential medicines affordable to its people, as well as becoming a centre for manufacturing excellence with the highest quality standards. The joint venture between the two companies led to the creation of Quality Chemical Industries Limited (QCIL) in 2005, with the state-of-the-art pharmaceutical manufacturing facility based in Luzira, being officially commissioned in 2007. QCIL has the highest levels of Quality standards and Good Manufacturing Practices (GMP) and it was pre-qualified by the World Health Organisation (WHO) for both plant and product in 2010 as an additional contract manufacturing site for Cipla Ltd. QCIL was again inspected by the World Health organisation in late 2012 and passed with flying colours.

QCIL has been recognized both locally and on the African continent for the various achievements it has attained in impacting on the business and health sectors in Africa. In 2012 the Ministry of Health in Uganda recognized QCIL for its outstanding contribution to the development of the pharmaceutical industry in the country. On the continental scene, QCIL attained the 2012 African Business Leadership Award (ABLA) of the year, a highly prestigious award that is organised by the African Development Bank. In the same year QCIL went a step further by attaining the Africa Award for Entrepreneurship where the company won the biggest category of ‘Transformational business of the year’. This event was held in Accra, Ghana and was organised by the African Leadership Network (ALN) which is a premier community of young dynamic and influential leaders in Africa.


Press Release

Coopers U Ltd

QCIL 2011 All rights Reserved | Declaimer